It will take all of us, working together, to urgently propel research to make ALS a livable disease until new treatments and a cure are ultimately found.
This month, learn more about the latest news and updates on oral edaravone, the status of NurOwn, and numerous ALS clinical trials.
BrainStorm Cell Therapeutics announced the company has received a refusal to file letter from the U.S. Food and Drug Administration regarding the company's New Biologics License Application (BLA) for NurOwn for the treatment of ALS.
Continuous monitoring of certain biomarkers in people with ALS may inform about the risk of disease progression and the response to edaravone, according to interim data from the ongoing REFINE-ALS biomarker study.
The Northeast Amyotrophic Lateral Sclerosis (NEALS) Consortium held its 21st annual meeting Nov. 1-3, bringing together clinicians, researchers and consortium members to share the latest research and findings in the care of ALS.
The ALS Association supports a wide breadth of specific fields of study that are critical to advancing ALS research. From genetics and biomarkers to assistive technology and clinical studies, the Association continues to be the largest philanthropic funder of ALS research worldwide.
This survey will capture the experiences of people living with ALS and their caregivers who have sought health insurance coverage for ALS care, services, treatments, equipment, and supplies. The insight and experiences shared through ALS Focus surveys shows The ALS Association which tools will best support advocacy for stronger coverage of ALS care in the future.
People with ALS and current caregivers in the U.S. are invited to participate in this ALS Focus Insurance and Payment for ALS Care Survey through December 16, 2022.
Register to participate in future surveys HERE and let your voice be heard.
Clinical research is the only way that promising laboratory science can be translated into treatments and cures for ALS and other neurological diseases. People with ALS, along with family members and caregivers, are essential partners in this research. For the most accurate and up-to-date information on both federally and privately funded clinical studies focusing on ALS and other similar motor neuron diseases, visit our website.
The National ALS Registry may be the single largest ALS research project ever created and is designed to identify ALS cases from throughout the entire United States. Every person living with ALS in the US can take part and there is no fee to participate.
The ALS Association partners with the Northeast ALS Consortium (NEALS) to provide educational webinars for people with ALS, caregivers, and the broader ALS community. Topics include updates on clinical trials, best practices for clinical care, and current research efforts in ALS causes and treatments.
For more detail about current ALS research, the projects we fund, and the numerous focus areas we support, visit als.org/research.
Stay up to date with the latest ALS care news by signing up for our quarterly e-newsletter, Care Matters.
We welcome all feedback, comments and questions you may have on anything about the information provided, suggestions of topics you would like to see in future newsletters or thoughts to help us improve. Please email us at communication@alsa-national.org.